Business Context and Reporting Period
Company: Gyrodyne, LLC (GYRO)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Gyrodyne is a limited liability company managing a portfolio of medical office and industrial properties in Suffolk (Flowerfield) and Westchester (Cortlandt Manor) Counties, New York. The Company operates under a liquidation basis of accounting, with a strategic plan to pursue entitlements to enhance property values, sell assets, settle debts, and distribute proceeds to shareholders before dissolving. The estimated liquidation timeline has been extended to December 31, 2028.
Key Financial Metrics
| Metric | December 31, 2025 | December 31, 2024 |
|---|---|---|
| Net Assets (Liquidation Basis) | $25,858,997 | $30,596,313 |
| Estimated Distribution Per Share | $11.76 | $13.91 |
| Real Estate Held for Sale (Net Realizable Value) | $53,990,000 | $50,388,000 |
| Cash and Cash Equivalents | $4,529,597 | $5,899,232 |
| Total Liabilities | $32,831,704 | $26,063,778 |
| Mortgage Loans Payable | $10,868,531 | $11,169,922 |
| Estimated Liquidation & Operating Costs (Net of Receipts) | $17,334,618 | $11,089,746 |
| Annual Base Rent (2025) | $2,341,687 | N/A |
| Occupancy Rate | 82% | 82% |
Material Changes Versus Prior Period
- Decrease in Net Assets: Net assets decreased by approximately $4.74 million ($13.91 to $11.76 per share) primarily due to:
- Increased estimated liquidation and operating costs of ~$3.5 million to accommodate a two-year timeline extension to 2028.
- A $4.02 million closing credit liability for infrastructure costs (sewer treatment plant) associated with the B2K sale agreement.
- Increased retention bonuses and selling costs (~$479,000) and additional land development fees (~$190,000).
- Real Estate Valuation: The net realizable value of real estate increased by $3.6 million, driven by market conditions and entitlement status, partially offsetting the increase in liabilities.
- Capital Structure: The Company completed a rights offering in March 2024 (reported in 2024 changes) raising ~$4.4 million net proceeds. In 2025, no new equity was issued.
- Debt: Total mortgage debt decreased slightly due to principal payments. A 2023 mortgage loan was modified in late 2025 to extend the term by 24 months with a revised interest rate of 15%.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Guidance
- Liquidation Timeline: Management now estimates the liquidation process will conclude by December 31, 2028, extended from the previous 2026 target due to regulatory delays and the B2K agreement terms.
- Projected Distributions: Based on current estimates, the Company anticipates a final cash balance of approximately $25.9 million, equating to $11.76 per share. This is subject to significant uncertainty regarding asset sale prices and future costs.
- Capital Needs: Management believes additional capital may be required to fund operations through 2028 absent sufficient working capital from property sales or loan modifications.
Material Risks and Contingencies
- Article 78 Proceeding: An ongoing legal challenge by the Village of Head of the Harbor and others seeks to annul the preliminary subdivision approval for the Flowerfield property. While the Supreme Court dismissed the petition in October 2024, petitioners have appealed. The outcome and timeline of this proceeding are critical to the sale of Flowerfield.
- B2K Sale Agreement: A Purchase and Sale Agreement for ~49 acres of Flowerfield vacant land was signed with B2K Smithtown LLC. The deal is contingent on subdivision and site plan approvals. The purchase price is estimated between $24 million and $28.74 million, subject to a $4.02 million credit for infrastructure costs.
- Shareholder Activism: The Company resolved a proxy contest with Star Equity Fund, LP via a "Star Agreement" in October 2025, which restricts Star Equity's ability to nominate directors or solicit proxies until late 2026/2027.
- Settlement Restrictions: A 2015 class action settlement prohibits selling properties below their December 2014 appraised values, which could limit sale options if market values decline.
Investor Verification Checklist
- Article 78 Appeal Status: Verify the current status of the appeal regarding the Flowerfield subdivision approval, as this is a primary blocker to the B2K sale and overall liquidation.
- B2K Agreement Contingencies: Confirm the progress on the subdivision and site plan approvals required to close the B2K transaction and the likelihood of the $4.02 million infrastructure credit being realized.
- Liquidity Runway: Assess whether the current cash balance (~$4.5 million) is sufficient to cover operating costs, entitlement fees, and debt service through the extended 2028 timeline without additional capital raises.
- Debt Modification Terms: Review the specific terms of the modified 2023 mortgage loan (15% interest rate) and the impact on future cash flows.
- Lease Expirations: Monitor the 52% of annual rental revenue up for renewal in 2026 and the risk of tenant defaults or non-renewals impacting cash flow.